Literature DB >> 1390232

Modulation of tissue factor on human monocytes by cisplatin and adriamycin.

J Walsh1, H R Wheeler, C L Geczy.   

Abstract

Coagulation disorders have been associated with the use of chemotherapeutic drugs. Pharmacological doses of cisplatin and adriamycin directly induced low levels of procoagulant on normal human blood monocytes and on a human myelomonocytic cell line, RC2a. Activity was maximal after 24 h and was not due to cell lysis as increasing drug doses which decreased cell viability were less effective. Procoagulant induction was markedly enhanced in the presence of bacterial lipopolysaccharide (LPS), with as little as 10-100 pg/ml LPS potentiating the cisplatin response by 2-5-fold and more than doubling the adriamycin response. Greater than 90% of the procoagulant activity was membrane-bound tissue factor as indicated by the factor VII-dependent generation of factor Xa by viable cells and by the neutralization of this activity by a monoclonal antibody to tissue factor. Tissue factor antigen was measured simultaneously by immunohistochemical staining and by cell ELISA. Blood monocytes activated with LPS expressed high levels of tissue factor antigen; by contrast, adriamycin and cisplatin did not appear to induce antigen expression, but to enhance the specific activity of that already present. Results suggest that membrane alterations which occur following treatment with DNA/RNA intercalating drugs, may result in a highly active form of monocyte/macrophage tissue factor which may contribute to the complications caused by activated coagulation. Secondary Gram-negative infection or cytokines released by an active immune response to a tumour may contribute to the procoagulant potential of these cytotoxic drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1390232     DOI: 10.1111/j.1365-2141.1992.tb02978.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Chemotherapy-induced vascular toxicity--real-time in vivo imaging of vessel impairment.

Authors:  Hadas Bar-Joseph; Salomon Marcello Stemmer; Ilan Tsarfaty; Ruth Shalgi; Irit Ben-Aharon
Journal:  J Vis Exp       Date:  2015-01-07       Impact factor: 1.355

2.  Aortic thrombosis resolved with enoxaparin in a patient treated with cisplatin-based regimen for small cell lung cancer.

Authors:  Sang Ouk Chin; Jae Jin Lee; Yeon Hee Hwang; Jae Joon Han; Chi Hoong Maeng; Sun Kyung Baek; Cheong Woong Choi
Journal:  Int J Hematol       Date:  2010-04-29       Impact factor: 2.490

Review 3.  Pathogenesis of thrombosis in patients with malignancy.

Authors:  A Falanga; M B Donati
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 4.  Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2020-09-09       Impact factor: 2.490

5.  A case of acute aortic thrombosis after cisplatin-based chemotherapy.

Authors:  Suk Jae Hahn; Jin Young Oh; Jeung Sook Kim; Do Yeun Kim
Journal:  Int J Clin Oncol       Date:  2011-04-01       Impact factor: 3.402

6.  Venous thromboembolism (VTE) and glioblastoma.

Authors:  Shlomit Yust-Katz; Jacob J Mandel; Jimin Wu; Ying Yuan; Courtney Webre; Tushar A Pawar; Harshad S Lhadha; Mark R Gilbert; Terri S Armstrong
Journal:  J Neurooncol       Date:  2015-05-19       Impact factor: 4.130

Review 7.  New insights into cancer-associated thrombosis.

Authors:  Tarek Sousou; Alok A Khorana
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-03       Impact factor: 8.311

Review 8.  Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.

Authors:  Rohit Moudgil; Edward T H Yeh
Journal:  Can J Cardiol       Date:  2016-02-02       Impact factor: 5.223

9.  Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer.

Authors:  Yun-Gyoo Lee; Eunyoung Lee; Inho Kim; Keun-Wook Lee; Tae Min Kim; Se-Hoon Lee; Dong-Wan Kim; Dae Seog Heo
Journal:  Cancer Res Treat       Date:  2015-01-02       Impact factor: 4.679

10.  Doxorubicin-induced vascular toxicity--targeting potential pathways may reduce procoagulant activity.

Authors:  Irit Ben Aharon; Hadas Bar Joseph; Moran Tzabari; Boris Shenkman; Nahid Farzam; Mattan Levi; Ruth Shalgi; Salomon M Stemmer; Naphtali Savion
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.